Drug Name |
Mitomycin |
Drug ID |
BADD_D01478 |
Description |
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix.[A193419] Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies.[A193419]
Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC)[L12867] - as well as adjunctly to _ab externo_ glaucoma surgeries. |
Indications and Usage |
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).[L12867] |
Marketing Status |
approved |
ATC Code |
L01DC03 |
DrugBank ID |
DB00305
|
KEGG ID |
D00208
|
MeSH ID |
D016685
|
PubChem ID |
5746
|
TTD Drug ID |
D0Y0GH
|
NDC Product Code |
72819-154; 65050-0058; 0143-9135; 68001-390; 68083-483; 69448-003; 68254-0016; 25021-252; 69448-001; 25021-250; 25021-251; 65219-564; 68083-502; 71288-138; 72493-103; 71288-137; 73212-036; 0143-9136; 0143-9279; 69448-002; 72819-153; 58623-0045; 62158-0005; 68083-484; 72819-152; 0143-9280; 49771-002; 65219-568; 68001-389; 38779-0553; 51927-0286; 71052-644; 71288-139; 53183-7010; 16729-115; 16729-116; 68001-391; 51552-1509; 65219-566; 16729-108 |
UNII |
50SG953SK6
|
Synonyms |
Mitomycin | Mitomycin C | Mitomycin-C | Mitocin-C | Mitocin C | MitocinC | NSC-26980 | NSC 26980 | NSC26980 | Ametycine | Mutamycin |